Get the Stockscreener App
6.48
1.09%
0.07
Kezar Life Sciences Inc stock is traded at $6.48, with a volume of 11,132.
It is up +1.09% in the last 24 hours and down -4.14% over the past month.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
See More
Previous Close:
$6.41
Open:
$6.29
24h Volume:
11,132
Relative Volume:
0.30
Market Cap:
$47.45M
Revenue:
$7.00M
Net Income/Loss:
$-61.71M
P/E Ratio:
-0.7675
EPS:
-8.4433
Net Cash Flow:
$-56.66M
1W Performance:
-4.85%
1M Performance:
-4.14%
6M Performance:
+72.80%
1Y Performance:
+14.89%
1-Day Range:
$6.29
$6.6803
1-Week Range:
$6.29
$6.79
52-Week Range:
$3.5334
$7.45
Kezar Life Sciences Inc Stock (KZR) Company Profile
Name
Kezar Life Sciences Inc
Sector
Industry
Phone
650-822-5600
Address
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
6.48 | 47.45M | 7.00M | -61.71M | -56.66M | -8.4433 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-17-25 | Downgrade | Jefferies | Buy → Hold |
| Oct-17-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-11-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-16-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
| Jul-16-18 | Initiated | William Blair | Outperform |
View All
Kezar Life Sciences Inc Stock (KZR) Latest News
Kezar Life Sciences (KZR) to Release Earnings on Tuesday - Defense World
Highs Report: Can Kezar Life Sciences Inc maintain its current growth rate2026 Key Highlights & Weekly Breakout Watchlists - baoquankhu1.vn
If You Invested $1,000 in Kezar Life Sciences (KZR) - Stock Titan
Bull Bear: Is EEIQ still a buy after recent gains2026 Big Picture & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Analyst Downgrade: Is Kezar Life Sciences Inc undervalued by DCF analysis2026 Retail Activity & Daily Market Momentum Tracking - baoquankhu1.vn
Kezar Life Sciences Inc expected to post a loss of $1.23 a shareEarnings Preview - TradingView
Kezar Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | 2KZ0 | US49372L2097 - marketscreener.com
Enodia jumps ahead in Sec61 targeting, adds Kezar’s program - BioWorld MedTech
Spring break for biotech deals? - BioCentury
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Deal Watch: Enodia Turns To Kezar To Advance Sec61 Programs - Citeline News & Insights
Enodia acquires Sec61 assets from Kezar Life Sciences - bioworld.com
Enodia acquires Kezar’s Sec61 program assets for $127M potential By Investing.com - Investing.com Canada
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences - PharmiWeb.com
Kezar Divests Sec61 Program to Refocus on Core Pipeline - TipRanks
Enodia Therapeutics strengthens Sec61 portfolio through acquisition of preclinical assets from Kezar Life Sciences - marketscreener.com
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition Of Preclinical Assets From Kezar Life Sciences - TradingView
Kezar Life Sciences Sells Sec61 Program to Enodia Therapeutics for Upfront Cash, Up to $127M Milestones - TradingView
Kezar Life Sciences (NASDAQ: KZR) sells Sec61 assets to Enodia with $127M milestones - Stock Titan
Kezar Life Sciences (KZR) Price Target Decreased by 52.00% to 6.12 - MSN
Entry Recap: Is Kezar Life Sciences Inc a play on infrastructure spendingBear Alert & Verified Chart Pattern Signals - baoquankhu1.vn
How cyclical is Kezar Life Sciences Inc. (2KZ0) stock compared to rivalsMarket Sentiment Summary & Reliable Price Breakout Signals - Naître et grandir
Layoff Watch: Why is Kezar Life Sciences Inc stock going upTake Profit & Safe Capital Growth Tips - baoquankhu1.vn
Downgrade Watch: What are Kezar Life Sciences Incs recent SEC filings showingTrade Exit Report & Community Trade Idea Sharing - baoquankhu1.vn
KZR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quarterly Trades: Will CRISPR Therapeutics AG benefit from government policyJuly 2025 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
Aug Analyst Calls: Why is Kezar Life Sciences Inc stock going upInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Activity Recap: Is Kezar Life Sciences Inc undervalued by DCF analysisTrade Risk Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Volume: Is Kezar Life Sciences Inc undervalued by DCF analysisBull Run & Weekly Return Optimization Plans - baoquankhu1.vn
Buy Signal: Will Stratus Properties Inc benefit from current market trendsPortfolio Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR - Defense World
Will Kezar Life Sciences Inc. stock recover faster than peersProduct Launch & Technical Confirmation Alerts - mfd.ru
Kezar Life Sciences (NASDAQ:KZR) Shares Up 0.3% – What’s Next? - Defense World
How Kezar Life Sciences Inc. stock reacts to Fed rate cuts2025 Short Interest & Daily Profit Maximizing Tips - mfd.ru
Will Kezar Life Sciences Inc. benefit from government policyJuly 2025 EndofMonth & Community Trade Idea Sharing - mfd.ru
Is Kezar Life Sciences Inc. trading at a discountTrade Exit Summary & Long Hold Capital Preservation Plans - mfd.ru
What are Kezar Life Sciences Inc.’s recent SEC filings showingJuly 2025 Fed Impact & Consistent Growth Equity Picks - mfd.ru
Is Kezar Life Sciences Inc. stock positioned for long term growthTrade Exit Summary & Entry Point Strategy Guides - mfd.ru
Published on: 2026-02-09 08:28:44 - baoquankhu1.vn
Chipmakers Recap: What is the next catalyst for Kezar Life Sciences IncJobs Report & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Rating of “Reduce” from Analysts - Defense World
Sectors Review: Will Kezar Life Sciences Inc benefit from government policy2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - baoquankhu1.vn
What is the next catalyst for Kezar Life Sciences Inc.July 2025 News Drivers & Community Consensus Stock Picks - bollywoodhelpline.com
ETF Watch: Will OXLCG benefit from geopolitical trendsJuly 2025 Patterns & Low Drawdown Trading Techniques - baoquankhu1.vn
Growth Review: Should I hold or sell Kezar Life Sciences Inc now2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
Layoff Tracker: SonomaBio Downsizes To Extend Runway - BioSpace
Sentiment Watch: Why Kezar Life Sciences Inc stock could rally in 2025Market Activity Summary & Free Technical Confirmation Trade Alerts - Bộ Nội Vụ
Published on: 2026-01-12 22:48:52 - ulpravda.ru
Kezar Life Sciences (KZR) to Discuss Zetomipzomib with FDA - GuruFocus
Kezar Life Sciences: FDA Division Grants Type C Meeting To Discuss Development Of Zetomipzomib - Nasdaq
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - The AI Journal
Kezar Life Sciences Inc Stock (KZR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):